
BIOLOGIA MOLECULAR EN ADENOCARCINOMA RENAL (RCC). SU UTILIDAD PRONÓSTICA Y TERAPÉUTICA
Juan Javier Zudaire Bergera, Aníbal Rincón Mayans, Jorge Rioja Zuazu, Javier Barba Abad, Luis Romero Vargas, Rubén Algarra Navarro, Antonio Tienza Fernández, José Enrique Robles García, David Rosell Costa, José María Berián Polo, Juan Ignacio Pascual Piédrola
BIOLOGIA MOLECULAR EN ADENOCARCINOMA RENAL (RCC). SU UTILIDAD PRONÓSTICA Y TERAPÉUTICA
Renal cell adenocarcinoma requires different therapeutic pathways because it is one of the most therapy-resistant tumors, on the other hand it is biologically one of the most attractive tumors. Its pathological classification has a genetic base. There is an anomaly of the Von Hippel Lindau gene in 80% of adenocarcinomas, being this fact determinant to know the biological characteristics of tumor initiation and development, as well as the identification of factors susceptible to be used as therapeutic targets. Since 2005 a group of molecules have been used in the treatment of metastatic adenocarcinomas and, even though therapeutic results are significant but not clinically relevant yet, we are sure they are a key way for more efficient future developments.The present study tries to make a tour on the research of the biological anomaliesin renal adenocarcinoma with special emphasis in the Von HippelLindau gene.
Renal carcinoma / Molecular biology / Diana therapy / Small renal masses {{custom_keyword}} /
/
〈 |
|
〉 |